Next-generation sequencing for guiding clinical decision-making

Next-generation sequencing for guiding clinical decision-making

EMJ

3 years
647 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the application of next-generation sequencing for guiding cancer treatment decision-making. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Phase 3 DUO Study @ospniguarda
Phase 3 DUO Study @ospniguarda
Category: Chronic Lymphocytic Leukemia
0 Views
Cancer-News 31 minutes
Surgical Trial for RCC @CleClinicMD
Surgical Trial for RCC @CleClinicMD
Category: Kidney Cancer
2 Views
kidneycancer 54 minutes
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
Category: Acute Lymphoblastic Leukemia
0 Views
Memorial Sloan Kettering 1 hour
Do We Still Need The P-Value? @MDAndersonNews
Do We Still Need The P-Value? @MDAndersonNews
Category: Kidney Cancer
6 Views
kidneycancer 22 hours
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 23 hours
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
1 Views
Cancer-News 1 day
Importance of Paradigms for Precision Medicine @sloan_kettering
Importance of Paradigms for Precision Medicine @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 1 day
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
2 Views
Memorial Sloan Kettering 1 day
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
7 Views
Cancer-News 1 day
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
4 Views
Cleveland Clinic 1 day